Eribulin in soft-tissue sarcoma
Mené sur 452 patients atteints d'un liposarcome ou d'un léiomyosarcome de stade avancé, cet essai international de phase III compare l'efficacité, du point de vue de la survie globale, et la toxicité de l'éribuline par rapport à la dacarbazine
Sarcomas are unusual tumours that can occur at any anatomical site. Although they account for less than 1% of malignant tumours, they can be divided into more than 50 clinically and biologically distinct subtypes. Until recently, all soft-tissue sarcomas were treated the same way, but in the past decade, progress has been made in identifying clinical, histological, and molecular features to guide management. In a randomised open-label phase 3 trial in The Lancet, Patrick Schöffski and colleagues report that eribulin improves overall survival in patients with advanced leiomyosarcoma and liposarcoma.
The Lancet , commentaire, 2015